IN BRIEF: 4D Pharma Interim Loss Widens On R&D Costs Increase

Wed, 30th Sep 2020 12:04

4D Pharma PLC - Leeds-based pharmaceutical company - Loss for the six months to June 30 widens year-on-year to GBP13.7 million from GBP12.0 million. Research and development expenditure rises to GBP12.4 million from GBP10.8 million. Revenue GBP275,000 versus none generated a year ago. Cash and cash equivalents and short-term deposits GBP10 million at June-end.

Current stock price: 153.50 pence

Year-to-date change: up 54%

By Tapan Panchal; tapanpanchal@alliancenews.com

Related Shares

More News

15 Feb 2023 14:21

IN BRIEF: 4D Pharma shares cancelled from trading on London's AIM

4D Pharma PLC - Leeds-based pharmaceutical firm - Notes cancellation of its shares on AIM from Thursday, after it entered into administration in June ...

3 Feb 2023 15:17

TRADING UPDATES: GCP Infra hails NAV rise; Jadestone profits from oil

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

9 Jan 2023 15:58

UK shareholder meetings calendar - next 7 days

30 Dec 2022 17:21

4D Pharma seeks approval for equity fundraise to lift suspension

(Alliance News) - 4D Pharma PLC on Friday said it was seeking shareholder approval for a USD15.0 million cash raise, as it works to lift its suspensio...

16 Nov 2022 17:00

4D Pharma says trial results show Blautix eases IBS symptoms

(Alliance News) - 4D Pharma PLC said on Wednesday that its Blautix phase 2 clinical trial results showed the treatment had a positive effect on suffer...